



Leylands Medical Centre Monthly Roundup: November 2025

Your Monthly Catch-Up on What's Happening in Primary Care

New and updated guidance

NICE sepsis (NG51 update) – due 19 Nov: NICE plans to split sepsis guidance by population (adults/NEWS2, pregnancy, CYP); watch out for new referral/assessment pathways later this month.

[Suspected sepsis: recognition, diagnosis and early management](#)

No other new hot topics this month, so last months updates appended below for reference

NICE NG106 – Heart failure: includes new recommendations for heart failure with preserved and mildly reduced ejection fraction; emphasises wider use of mineralocorticoid receptor antagonists and monitoring

[Chronic heart failure in adults: diagnosis and management | Guidance | NICE](#)

NICE CG185 – Bipolar disorder: advises male patients taking valproate to use effective contraception during treatment and for three months after stopping.

[Bipolar disorder: assessment and management | Guidance | NICE](#)

NICE NG60 – HIV testing: encourages opportunistic testing based on local prevalence data from UKHSA surveillance.

[Increasing uptake among people who may have undiagnosed HIV | Guidance | NICE](#)

The Leylands view:

Sepsis was discussed at the last PLT and the vitals/lifestyle templates for adults and children have been updated to reflect this - please do feedback any issues or comments regarding these.

Immunisation & vaccines

Uncertain or imperfect immunisations? Here's what to do: updated UKHSA flow-chart
[Vaccination of individuals with uncertain or incomplete immunisation - GOV.UK](#)

The Leylands view:

Flu vaccination season is in full swing - please remember to vaccinate opportunistically when you can

There is also significant investment underway in reviewing our approach to childhood vaccinations.

The MECC template doesn't cover childhood imms, and as a practice low uptake is a major challenge for us so please have this discussion with new parents at every opportunity

Safety alerts & BNF changes

MHRA Safety Roundup (Oct 2025): #MedSafetyWeek (3–9 Nov) and an isotretinoin baseline survey (due 16 Nov) for services that prescribe

MHRA Safety Roundup October 2025

BNF – September 2025 update: highlights include update guidance on antibacterial therapy and notifiable disease, change to criteria for severity of acute asthma attacks, salbutamol/terbutaline - reminder of risks of overuse and updated asthma guidance

<https://bnf.nice.org.uk/about/changes/>

The Leylands view:

Key takeaway from medsafetyweek is about flagging adverse events via the Yellow Card service available directly from SystmOne - ask if you don't know how to do this. This is not just about flagging new/unknown issues but it allows collating of volume of side effects/adverse events.

Notifiable disease pathway is via GP Assist. SABA overuse audit is pending - if anyone wants to do this as a QIA with pharmacy support - please shout out.

Digital & political developments

Online access during core hours: from 1 Oct 2025, GP practices must keep online consultation systems open from 8:00–18:30; phone and walk-in options remain.

[NHS England » Online consultations – frequently asked questions and support resources](#)

The Leylands view:

Work underway via the GP improvement programme to review our approach to appointments as a whole, and OC's will be part of this. Watch this space... If anyone has lived experience of working in practices doing total triage, please share your experiences.

GP Connect & patient charter: practices must enable read-only access for other providers and allow pharmacies to send consultation summaries; a patient charter will set expectations.

[NHS England » Changes to the GP Contract in 2025/26](#)

The Leylands view:

Lots of pharmacy BP's coming through to S1. This is meant to be for case finding, but many of these are already known to have HTN. Furthermore, many BP's seem to be taken during flu vaccination clinics. This complicates matters. Tom is working on a SOP to streamline these which will be shared once complete.

If you want to chat further about any of the topics above and how they might affect impact Leylands, feel free to bring up at PLT, or approach one of the Partners or Tom
